COMMUNIQUÉS West-GlobeNewswire

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

27/03/2024 - 21:01

Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES- [...]

TFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical Programs

27/03/2024 - 21:01

Eight of Eight Patients Successfully Transitioned from Oral Tacrolimus to TFF TAC with No Sign of Acute Rejection at Reduced Systemic Exposures Data from TFF VORI Phase 2 and EAP Program Continue to Demonstrate [...]

Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

27/03/2024 - 21:01

Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data demonstrating the [...]

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

27/03/2024 - 21:01

BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

27/03/2024 - 21:01

Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026 Executed private placement financing [...]

STRATA Skin Sciences Reports Fourth Quarter and Full-Year 2023 Earnings

27/03/2024 - 21:01

Company to host conference call and webcast today, March 27, 2024, at 4:30 PM ET HORSHAM, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN) (“STRATA” or “the Company”), a medical [...]

Inventiva reports its 2023 full-year results

27/03/2024 - 21:00

Revenues at €17.5 million for the full year of 2023 up 43.4% compared to €12.2 million for 2022 Cash and cash equivalents at €26.9 million, short-term deposits at €0.01 million 1 , and long-term deposit at €9.0 million [...]

Inventiva publie ses résultats annuels 2023

27/03/2024 - 21:00

Chiffre d’affaires de 17,5 millions d’euros pour l’année 2023, en hausse de 43,4 % par rapport à 12,2 millions d’euros en 2022 Trésorerie et équivalents de trésorerie de 26,9 millions d’euros, dépôt à court terme de 0, [...]

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

27/03/2024 - 21:00

SUNNYVALE, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]

BioSyent Announces Grant of Restricted Share Units

27/03/2024 - 23:34

MISSISSAUGA, Ontario, March 27, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved a grant of 66,020 Restricted Share Units “RSUs” to [...]

By 2035, Canada could have the most enviable healthcare system in the world if obesity is recognized as a chronic disease, predicts Obesity Canada

27/03/2024 - 22:33

EDMONTON, Alberta, March 27, 2024 (GLOBE NEWSWIRE) -- Nearly 30,000 deaths from noncommunicable diseases in Canada in 2019, were due to high body mass index (BMI), most related to diabetes, cardiovascular disease, and [...]

Beacon Behavioral Partners Expands to Florida with the Addition of The Neuropsychiatry & TMS Group

27/03/2024 - 22:22

The network of physician-driven psychiatric practices continues to expand across the Southeastern United States to enhance patient care BATON ROUGE, La., March 27, 2024 (GLOBE NEWSWIRE) -- Beacon Behavioral Partners , a [...]

American Shared Hospital Services Reports Fourth Quarter 2023 Financial Results

27/03/2024 - 22:12

- Acquisition of 3 Rhode Island Radiation Therapy Cancer Centers progressing toward closing- - International Cancer Center equipment upgrade completed in Ecuador, Opening new Puebla, Mexico Center in Q2- - Lease [...]

Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise

27/03/2024 - 22:05

TORONTO and HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or “NurExone”), is pleased to announce that, the Company completed a combined exercise and [...]

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

27/03/2024 - 21:41

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX ), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported financial results for the [...]

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

27/03/2024 - 21:30

MALVERN, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

27/03/2024 - 21:17

Initiated enrollment of the BACKBEAT global pivotal study evaluating AVIM therapy (also known as BackBeat Cardiac Neuromodulation Therapy) in hypertensive pacemaker patients in collaboration with Medtronic, plc (NYSE: [...]

Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity

27/03/2024 - 21:15

Company to host conference call on Thursday, March 28, 2024 at 8:00 a.m. ET BOSTON and ATLANTA, March 27, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage [...]

Spectral AI Announces 2023 Fourth Quarter and Full Year Financial Results

27/03/2024 - 21:10

2023 Research & Development Revenue of $18.1 Million Expected to Increase to $28.0 Million in 2024 Commercialization Underway with Revenue Expected in 2H 2024 for DeepView AI ® -Burn Indication in the UK On Track [...]